Amycolatopsis serissoides (Amycolatopsis serissoides) WQ 127309 and application of Amycolatopsis serissoides (Amycolatopsis serissoides (Amycolatopsis serissoides (Amycolatopsis serissoides) WQ 127309
By discovering and isolating the new strain of Amycolatopsis baimaensis WQ 127309, the problem of mitigation and bacterial resistance of existing antibiotic research and development has been solved, and effective inhibition of a variety of bacteria and tumor cells has been achieved, demonstrating its Broad-spectrum antibacterial and anti-tumor activities have important application prospects.
Patent Information
- Application Number
- CN202411375771.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-09-30
Smart Images

Figure CN119060905A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and specifically relates to a potential new species of Amycolatopsis baimaensis (Amycolatopsis baimaensis) WQ 127309 and an application thereof. Background Art
[0002] Since their discovery, antibiotics have played an important role in preventing and treating bacterial infections and improving the quality of human life. However, with the widespread use or abuse of antibiotics, bacterial resistance has become rampant, seriously threatening human life and health. The reduction in investment in the research and development of new antibiotics has exacerbated the severity of the problem of drug resistance. Although many aspects of research have been carried out on bacterial resistance, finding new antibiotics or their derivatives is still an important way.
[0003] Nearly two-thirds of the antibiotics currently used in clinical practice come from actinomycetes, of which more than half come from Streptomyces. As an important rare actinomycete, Amycolatopsis has abundant secondary metabolites (polyketides, glycosides, glycopeptides, macrolides, polyphenols, etc.) and diverse structures. It is an important source of antibacterial, anticancer, antihyperglycemic, and immunosuppressant drugs, such as vancomycin and rifamycin, which are widely used in clinical practice (Lazzarini, A.; Cavaletti, L.; Toppo, G.; Marinelli, F. Rare genera of Actinomycetes as potential producers of new antibiotics. Anton. Leeuw. Int. J. Gen. 2000, 78, 399-405; Barna, JC; Williams, DH The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu. Rev. Microbiol. 1984, 38, 339-357). The potential of Amycolatopsis to synthesize natural products needs to be systematically analyzed and explored.
[0004] With the increasing drug resistance of drug-resistant strains and the slowdown of antibiotic research and development, the discovery of new antibiotics or anti-tumor drugs is still a hot spot in microbial drug research and development. Therefore, it is increasingly important to discover more new strain resources. New species of Pseudomonas and their secondary metabolites have important research value. Summary of the invention
[0005] The purpose of the present invention is to overcome the deficiencies in the prior art and provide a new strain of Amycolatopsis spp. which has broad-spectrum antibacterial and anti-tumor activities and has broad development space and application prospects.
[0006] In a first aspect, the present invention claims a potential new species of the genus Amycolatopsis.
[0007] The new species of the genus Amycolatopsis claimed for protection in the present invention is specifically a rare actinomycete strain isolated and screened from a soil sample in the habitat of golden monkeys in Baima Snow Mountain, Yunnan. The strain is named Amycolatopsis baimaensis WQ 127309 and is deposited in the China Center for Type Culture Collection (CCTCC), address: No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province, on the campus of Wuhan University, with the deposit number of CCTCC M 20241536.
[0008] The Amycolatopsis baimaensis WQ 127309 is a Gram-positive aerobic bacterium. On medium No. 38, it develops abundant intrabasal hyphae, produces brown or brown pigments, and its aerial hyphae are white. It produces abundant spores on medium ISP4. The optimal growth temperature of the strain is 28° C., and the optimal pH is 7.0.
[0009] In a second aspect, the invention claims a culture.
[0010] The culture claimed in the present invention is the culture of Amycolatopsis baimaensis WQ 127309 as mentioned above, which is a substance obtained by culturing the Amycolatopsis baimaensis WQ 127309 in an actinomycete culture medium.
[0011] In the above culture, the substances include the Amycolatopsis baimaensis WQ127309 bacteria itself and the metabolites of the Amycolatopsis baimaensis WQ 127309 culture.
[0012] In the above culture, the actinomycete culture medium can be a solid culture medium or a liquid culture medium.
[0013] The term "culture" refers to a general term for liquid or solid culture media that have a microbial population after artificial inoculation and culture. That is, the product obtained by growing or amplifying microorganisms, which can be a biologically pure culture of microorganisms, or it can contain a certain amount of culture medium, metabolites or other components produced during the culture process. The term "culture" also includes a subculture obtained by subculturing microorganisms, which can be a culture of a certain generation or a mixture of several generations.
[0014] In a specific embodiment of the present invention, the actinomycete culture medium is specifically a modified 312 culture medium.
[0015] In a third aspect, the present invention claims a metabolite.
[0016] The metabolite claimed in the present invention is the metabolite of Amycolatopsis baimaensis WQ 127309 described in the first aspect above.
[0017] The term "metabolite" refers to the primary metabolites and / or secondary metabolites produced during the metabolism of microorganisms. Primary metabolites refer to the process in which microorganisms absorb various nutrients from the outside world and generate substances and energy to maintain life activities through catabolism and anabolism. The products of primary metabolism are primary metabolites, such as monosaccharides or monosaccharide derivatives, nucleotides, vitamins, amino acids, fatty acids and other monomers, as well as various macromolecular polymers composed of them, such as proteins, nucleic acids, polysaccharides, lipids, etc. Secondary metabolism refers to the process in which microorganisms use primary metabolites as precursors to synthesize some substances that have no clear function in the life activities of microorganisms during a certain period of production. The products of secondary metabolism are secondary metabolites, most of which are compounds with relatively complex structures. According to their functions, they can be divided into antibiotics, hormones, alkaloids, and toxins.
[0018] In the fourth aspect, the present invention claims protection for the use of Amycolatopsis baimaensis WQ 127309 described in the first aspect above, or the culture described in the second aspect above, or the metabolite described in the third aspect above in inhibiting Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Proteus mirabilis, Pseudomonas aeruginosa, Bacillus subtilis, Candida albicans, Mycobacterium tuberculosis and Sarcina luteus.
[0019] In a fifth aspect, the present invention claims the use of Amycolatopsis baimaensis WQ 127309 described in the first aspect above, or the culture described in the second aspect above, or the metabolite described in the third aspect above in inhibiting the proliferation activity of tumor cells HepG2 and Hela cells.
[0020] Experiments have shown that the strain WQ 127309 of the present invention represents a new species of the genus Amycolatopsis, named Amycolatopsis baimaensis WQ 127309. The strain has the activity of inhibiting Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Proteus mirabilis, Pseudomonas aeruginosa, Bacillus subtilis, Candida albicans, Mycobacterium tuberculosis and Sarcina luteus, and has significant activity of inhibiting proliferation of tumor cells HepG2 and Hela. The present invention is of great significance for controlling Gram-positive and Gram-negative bacterial infections, fungal infections and tumor cell proliferation activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 A phylogenetic tree constructed using the NJ method for the 16S rDNA sequences of Amycolatopsis baimaensis WQ 127309 of the present invention and related officially published typical strains;
[0022] Figure 2 A phylogenetic tree constructed from the genomes of Amycolatopsis baimaensis WQ 127309 and related strains of the present invention;
[0023] Figure 3 The results of the inhibition of Amycolatopsis baimaensis WQ 127309 on Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Proteus mirabilis, Pseudomonas aeruginosa, Bacillus subtilis, Candida albicans, Mycobacterium tuberculosis and Sarcina luteus. CK is the negative control DMSO; 1 and 2 are two replicates of the strain fermentation broth extract;
[0024] Figure 4 The invention discloses the proliferation inhibition rate of the fermentation product of Amycolatopsis baimaensis WQ 127309 on tumor cells and normal cells. DETAILED DESCRIPTION
[0025] The present invention will be further described in detail below in conjunction with the accompanying drawings and examples, but the scope of protection of the present invention is not limited to the contents described. Unless otherwise specified in the examples, all of the methods are conventional methods, and the reagents used are conventional reagents or reagents prepared according to conventional methods unless otherwise specified.
[0026] Example 1: Isolation of strain WQ 127309
[0027] (1) The separation medium and its components are as follows:
[0028] Glycerol 10.0 g, asparagine 1.0 g, K2HPO4 1.0 g, MgSO4·7H2O 0.5 g, CaCO3 0.3 g, multivitamin 0.03 g, trace salt (FeSO4·7H2O 0.1 g, MnCl2·4H2O 0.1 g, ZnSO4·7H2O0.1 g, dissolved in 100 mL water) 1.0 mL, agar 15.0, pH 7.2-7.4;
[0029] (2) Screening method
[0030] Soil was collected from the habitat of the Yunnan snub-nosed monkey in Baima Snow Mountain. Fresh soil samples were air-dried at 28°C for 7 days and dried at 85°C for 1 hour. 5 g of the dried sample was weighed and added to 95 mL of 0.1% Na4P2O7 (sodium pyrophosphate), and 100 mg / L of nystatin and 25 mg / L of nalidixic acid were added at the same time. The mixture was placed in a shaker at 28°C and 200 rpm for 1 hour to mix. The mixed sample was immediately treated with an ultrasonic cleaner for 30 seconds and then diluted to 10 -3 , 10 -4 and 10 -5 spare.
[0031] (3) Isolation and purification of bacterial strains
[0032] Take 0.2mL of dilution from each gradient and evenly spread it on the surface of the separation medium, invert it and put it in a constant temperature incubator, and culture it at 30℃ for 7-30 days. According to the characteristics of colony morphology, size, color, surface humidity, gloss, etc., select single colonies and inoculate them on YIM38 slant medium (medium ingredients: yeast extract 4.0g, glucose 4.0g, malt extract powder 2.5g, multivitamins 1.0mg, agar 15g, pH 7.2), and culture them for 3-7 days. By observing the color, morphology, size, texture (moist, dry, spores) and other characteristics of the colonies on the slant medium, remove the contaminated strains and duplicate strains with obvious miscellaneous bacterial colonies, record the numbers, and store the slant at 4℃.
[0033] The strain on the slant was purified using YIM 38 medium, and the bacterial cells were collected, suspended in 20% glycerol (v / v), and stored at -80°C.
[0034] Combined with the above screening methods, the strain isolated and purified in this experiment was WQ 127309.
[0035] Example 2: Molecular biological identification of strain WQ 127309
[0036] Lysis buffer for microorganism to direct PCR from Takara was used to prepare the lysate of strain WQ 127309. The lysate was used as the PCR template. The universal primers 27F (5′-AGAGTTTGATCCTGGCTCAG-3′) and 1492R (5′-GGTTACCTTGTTACGACTT-3′) for 16S rRNA gene amplification were used, and PCR amplification was performed using Green Taq Mix. The PCR amplification system (50 μL) was as follows: 25 μL Green Taq Mix, 2 μL DNA template, 1 μL each of the forward and reverse PCR primers, and 21 μL ddH2O. The PCR reaction conditions were: 94°C for 4 min; 94°C for 1 min, 56°C for 50 s, 72°C for 1.5 min, 32 cycles; 72°C for 10 min; and stored at 4°C. The PCR products were separated by 1% agarose gel electrophoresis, and DNA was purified using a gel recovery kit. The 16S rRNA gene fragment of strain WQ 127309 was transformed into E. coli DH5α using TA cloning technology, and the PCR products of positive clones were selected and sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing; the obtained sequences were compared in the EZbiocloud database to check the similarity between the strains and the effectively published strains, and the 16S rRNA gene sequences of similar strains were obtained. The phylogenetic tree was constructed by Neighbor-Joining using MEGA 11 software (see Figure 1 ), and the bootstrap value was set to 1000 to determine the phylogenetic status of the strains.
[0037] Strain WQ 127309 genome analysis. The complete genome of the strain was obtained by sequencing using the Illumina NovaSeq PE150 sequencing platform. The average nucleotide identity (ANI) with similar strains was calculated using the ANI Calculator in EzBioCloud. The DNA-DNA hybridization (dDDH) with similar strains was calculated using the recommended settings of GGDC. The phylogenetic tree of the strain and similar strains was constructed using TYGS to determine its taxonomic status.
[0038] The results showed that the strain WQ 127309 of the present invention was most closely related to the species of the genus Amycolatopsis of the family Pseudonocardiaceae of the Actinomycetes. The 16S rRNA gene sequence of the strain WQ 127309 of the present invention was similar to that of Amycolatopsis balhimycina FH1894 in the database. TThe highest similarity is 98.4%, which is lower than the limit of 98.65% for distinguishing prokaryotic microbial species (Kim M, Oh HS, Park SC, Chun J. Towards a taxonomic coherence between average nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of prokaryotes. Int J Syst Evol Microbiol 2014; 64: 346–351.). The results preliminarily revealed that the strain WQ 127309 of the present invention may represent a new species. The phylogenetic tree constructed with the 16S rRNA gene sequence of similar species ( Figure 1 ) showed that strain WQ 127309 and Amycolatopsis nivea KCTC39515 T and Amycolatopsis saslfeldensis DSM 44993 T The strain WQ 127309 was further compared with the genome sequences of typical strains of the genus Amycolatopsis, and a phylogenetic tree based on the genome sequence was constructed, and the ANI and dDDH values were calculated (Table 1). The strain WQ 127309 independently clustered into a branch, which was different from Amycolatopsis nivea KCTC 39515. T , Amycolatopsis saslfeldensis DSM 44993 T and Amycolatopsisechigonensis JCM 21831 TThe ANI values of the typical strains of the genus Amycolatopsis were all lower than 87.3%, and the dDDH values were all lower than 33%, which were far lower than the critical values for distinguishing prokaryotic microbial species (ANI < 95-96%; dDDH < 70%) (Kim M, Oh HS, Park SC, Chun J. Towards a taxonomic coherence between average nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of prokaryotes. Int J Syst Evol Microbiol 2014; 64: 346–351.). The strain WQ 127309 was confirmed to represent a new species of the genus Amycolatopsis, and was named Amycolatopsis baimaensis WQ 127309. T , the Chinese name is Amycolatopsis baima. Strain WQ 127309 is the model strain.
[0039] Table 1.WQ 127309 T Comparison with genome information of similar typical strains
[0040]
[0041]
[0042] Amycolatopsis baimaensis WQ 127309 T It was deposited in the China Center for Type Microbiological Culture Collection on July 15, 2024, with the deposit number CCTCC M 20241536.
[0043] Example 3: Determination of antibacterial activity of strain WQ 127309
[0044] (1) Experimental Materials
[0045] Seed culture medium (g / L): glucose 3.12g, KNO3 0.6g, KH2PO4 1g, K2HPO4 1g, MgSO4·7H2O0.2g, pH about 7.0.
[0046] Improved No. 312 fermentation medium (g / L): glucose 60 g, glycerol 30 g, soybean powder 20 g, KH2PO4 0.5 g, MgSO4·7H2O 0.5 g, CaCO3 3 g, soluble starch 5 g, yeast extract 30 g, peptone 10 g, pH = 7.2.
[0047] Indicator strains: laboratory-preserved Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Proteus mirabilis, Pseudomonas aeruginosa, Bacillus subtilis, Candida albicans, Mycobacterium tuberculosis and Sarcina luteus.
[0048] (2) Experimental methods
[0049] WQ 127309 was activated with seed culture medium and cultured at 30°C and 200rpm for 3 days. The cultured bacterial liquid was inoculated into 100mL fermentation medium at 1% inoculum (volume ratio) and cultured at 30°C and 200rpm for 7-15 days. After fermentation, the bacterial cells and fermentation liquid were collected by centrifugation, and the fermentation liquid was extracted with an equal volume of ethyl acetate. The extracts were combined after three extractions, and 10mL of methanol was added to resuspend the fermentation liquid extract after rotary evaporation to obtain the fermentation liquid extract; the bacterial cells were soaked in 50mL of acetone, ultrasonicated for 30 minutes, extracted three times and combined, and 10mL of methanol was added to resuspend the bacterial extract after rotary evaporation to obtain the bacterial extract; the fermentation liquid extract and the bacterial extract resuspended liquid were combined, and the fermentation product of strain WQ 127309 was obtained by rotary evaporation. An appropriate amount of DMSO was added to resuspend the fermentation product, and the antibacterial activity of the fermentation product against the indicator bacteria was determined by the filter paper method. DMSO was used as a negative control, and 2 replicates were set for each indicator bacteria. The results were observed for about 24 hours and the diameter of the inhibition zone was recorded.
[0050] (3) Experimental results
[0051] The results showed that the fermentation product of strain WQ 127309 had significant inhibitory activity against Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Proteus mirabilis, Pseudomonas aeruginosa, Bacillus subtilis, Candida albicans, Mycobacterium tuberculosis and Sarcina luteus (see Figure 3 ).
[0052] Example 4: Determination of antitumor activity of strain WQ 127309
[0053] (1) Experimental Materials
[0054] Test cell lines: human liver cancer cell line (HepG2), human cervical cancer cell line (Hela), mouse macrophage cell line (Raw 246.7), African green monkey kidney cell line (Vero), culture conditions are 90% DMEM medium, 10% fetal bovine serum, 1% double antibody (penicillin, streptomycin), 37°C, 5% CO2.
[0055] (2) Experimental methods
[0056] MTT assay to detect cell activity:
[0057] The above four types of cells were taken out of liquid nitrogen, thawed quickly in a 37°C water bath, centrifuged at 1000 rpm, added with newly prepared culture medium (DMEM+10% FBS+1% double antibody), gently pipetted and mixed, inoculated into T25 flasks, and cultured in a 5% CO2, 37°C cell culture incubator. When the cell coverage exceeded 80%, cells in good condition were inoculated into 96-well plates (HepG2 about 1×10 4 cells / well, Hela and Vero about 5×10 3 cells / well, Raw 246.7 approximately 1×10 3 cells / well), and after culturing for 24 h, the cells were treated with different concentrations of crude extract of strain WQ 127309 fermentation extract (the final concentration of crude extract was 1 mg / mL, 0.1 mg / mL, and 0.01 mg / mL), with 0.1% DMSO treatment group as negative control, and 3 μM paclitaxel (PTX) treatment group as positive control, and 3 replicate wells were set for each treatment; after continuing to culture for 3 days, the cells were subjected to MTT analysis.
[0058] Add 10% MTT reagent to the supernatant of the crudely extracted cell culture 96-well plate, that is, add 20 μL mg / mL MTT to each well and continue culturing for 4 hours, aspirate the liquid in the well plate, then add 200 μL DMSO to each well, shake to fully dissolve the crystals, detect the OD value at a wavelength of 490 nm with a microplate reader, and calculate the cell proliferation inhibition rate.
[0059] Cell survival rate = (1-experimental group OD / control group OD) × 100%
[0060] (3) Experimental results
[0061] The fermentation product of strain WQ 127309 has a strong inhibitory effect on the proliferation of HepG 2 and Hela cells, with an inhibition rate of more than 90% at a concentration of 1 mg / mL. In particular, for HepG 2 cells, the inhibition rate is much higher than the positive control. The crude extract of the fermentation extract of strain WQ127309 has little cytotoxicity to Raw 246.7 and Vero cells, less than 30% at different concentrations, especially for Raw 246.7 cells, there is almost no cell proliferation inhibition (see Figure 4 and Table 2).
[0062] Table 2.WQ 127309 T Proliferation inhibition rate of fermentation products on tumor cells and normal cells
[0063]
[0064] The experimental results show that the fermentation product of strain WQ 127309 can effectively inhibit the proliferation of cancer cells and has good anti-cancer activity. At the same time, it has low killing activity against normal cells and immune cells, and has potential cancer treatment value.
Claims
1. A potential new species of Amycolatopsis baimaensis WQ 127309, whose preservation number in the China Center for Type Culture Collection is CCTCC M 20241536.
2. The culture of Amycolatopsis baima WQ 127309 according to claim 1 is obtained by culturing Amycolatopsis baima WQ 127309 according to claim 1 in a bacterial culture medium.
3. The metabolites of Amycolatopsis baima WQ 127309 according to claim 1.
4. Use of the Amycolatopsis leucoderma according to claim 1, the culture according to claim 2 or the metabolite according to claim 3 in antibacterial aspects.
5. The use according to claim 4, characterized in that: The Amycolatopsis pseudowhite horse WQ 127309 has an inhibitory effect on Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Proteus mirabilis, Pseudomonas aeruginosa, Bacillus subtilis, Candida albicans, Mycobacterium tuberculosis and Sarcina luteus.
6. Use of the Amycolatopsis leucoderma of claim 1, the culture of claim 2 or the metabolite of claim 3 in anti-tumor cells.
7. The use according to claim 6, characterized in that: The Amycolatopsis leucoderma WQ 127309 has a significant effect of inhibiting cell proliferation on tumor cells HepG2 and Hela.
Citation Information
Patent Citations
Application of amycolatopsis sp. WP1 to preparation of Gram bacterium activity inhibitor
CN105168260A
New QD amycolatopsis sp. Species and application thereof
CN116286478A
Amycolatopsis sp. And application thereof
CN117887626A
Amycolatopsis sp., culture, metabolite, fungicide and application
CN118048276A
Amycolatopsis sp. Strain and Methods of Using the Same for Vanillin Production
US20130115667A1
Cited By
Amycolatopsis sp., culture, metabolite, fungicide and application
CN118048276A
Amycolatopsis sp., cultures, metabolites, inoculants, and uses
CN118048276B
